T0	Participants 129 211	patients with non-small-cell lung cancer after failure of first-line chemotherapy:
T1	Participants 351 399	patients with non-small-cell lung cancer (NSCLC)
T2	Participants 662 782	patients with advanced NSCLC, EGFR wild-type or unknown, PS 0-2, in whom initial cisplatin-based chemotherapy had failed
T3	Participants 1291 1385	147 patients were randomized (median age: 60Â±8 years, PS 0/1/2: 44/83/20 patients; males: 78%)